Kiora Pharmaceuticals Inc (KPRX)

NASD · Healthcare · Biotechnology · USA

Kiora Pharmaceuticals Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapies for retinal diseases. The company is advancing KIO-301, a small molecule designed to restore vision in patients with retinitis pigmentosa and other inherited retinal diseases. It is also developing KIO-104 for retinal inflammatory conditions and KIO-101 for ocular manifestations of autoimmune diseases.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Kiora Pharmaceuticals Inc stock.

Our verdict on KPRX

Undervalued: intrinsic value $3.08 per share, market price $0.93, margin of safety 69.8% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $3.08; the price of $0.93 is 70% below that value.

ETFs with the most weight in KPRX

More on KPRX

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than KPRX in Biotechnology

Is KPRX undervalued or overvalued?

KPRX is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $3.08; the price of $0.93 is 70% below that value.

What is the intrinsic value of KPRX?

$3.08 per share (as of the 2026-11-17 close), against a market price of $0.93. That is a margin of safety of 69.8%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.